| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We examined the in vitro screening system using natural product compound libraries and known drug libraries and found compounds that strongly suppress the HAT activity of p300, which is a therapeutic target for heart failure. Next, we performed whether these candidate compounds for the treatment of heart failure could inhibit the cardiomyocyte hypertrophy in cultured neonatal rat cardiomyocytes. We identified some of these compounds that possessed the more strongly and more myocardial-specific hypertrophic inhibitory effect at low concentrations. Furthermore, we found that ω3 fatty acids suppressed the progression of heart failure in myocardial infarction rat model.
|
